Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T14:05:35.473Z Has data issue: false hasContentIssue false

Delphi Panel on the Dimensions and Assessment of Functional Recovery in First-Episode and Early-Phase Schizophrenia Patients

Published online by Cambridge University Press:  14 April 2023

John M. Kane
Affiliation:
Feinstein Institutes for Medical Research-Northwell Health, Institute of Behavioral Science, New York, USA
Murat Yildirim
Affiliation:
H.Lundbeck A/S, Copenhagen, Denmark
Jessica Madera-McDonough
Affiliation:
Otsuka Pharmaceutical
Celso Arango
Affiliation:
Hospital General Universitario Gregorio Marañón, Child and Adolescent Department of Psychiatry, Madrid, Spain
Andrea Fagiolini
Affiliation:
Universita di Siena, Division of Psychiatry, Siena, Italy
Philip Gorwood
Affiliation:
Université de Paris, Institut Psychiatrie et Neurosciences de Paris, Paris, France
Navdeep Sahota
Affiliation:
OPEN Health, London, United Kingdom
Christoph U. Correll
Affiliation:
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell- Hempstead, Department of Psychiatry and Molecular Medicine, New York, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Functional recovery is a treatment goal that goes beyond symptomatic remission and encompasses multiple aspects of schizophrenia patients’ lives, including quality of life, physical, and mental functioning. There is evidence that long-acting injectable (LAI) treatments promote adherence and reduce rehospitalisation and functional decline, which could facilitate patients’ ability to reach functional recovery. Despite this, LAIs are underused in the first-episode (FEP) and early-phase (EP) patient population, due to physician hesitancy and concerns around stigma. A Delphi panel was held to gain expert consensus on an approach to the domains and assessment of functional recovery elements in FEP and EP schizophrenia patients.

A literature review and input from a steering committee of 5 experts in psychiatry informed statements development for a three-round modified Delphi process. Round one was conducted via one-to-one video conference interviews, and the successive rounds were conducted via electronic surveys, which enabled international collaboration. Statements on the different domains and assessment for functional recovery were presented to 17 psychiatrists, practicing in 7 countries (France, Italy, US, Germany, Spain, Denmark, and UK), experienced in the treatment of schizophrenia with LAIs. Several analysis rules determined whether a statement could progress to the next round and specified the level of agreement required to achieve consensus. Measures of central tendency (mode, mean) and variability (interquartile range) were reported back to help panelists look at their previous responses in the context of the overall group.

A consensus was reached (defined a priori as ≥80% agreement) on all 27 statements covering the dimensions, assessment, and level of achieved functional recovery for FEP and EP patients. The following domains are important to consider when assessing functional recovery: depression, aggressive behaviour, social interaction, family functioning, education/employment, sexual functioning, and leisure activities. Additionally, panellists reached consensus that dimensions should be minimally impairing, if present (excluding sexual functioning) and asked about at every encounter with the patient (excluding sexual functioning and leisure activities). In summary, this Delphi panel yielded agreement that functional recovery is multidimensional and should be assessed regularly as part of usual care on an individual patient level in FEP and EP schizophrenia patients.

Funding

Lundbeck Otsuka Alliance

Type
Abstracts
Copyright
© The Author(s), 2023. Published by Cambridge University Press